LB-100 is a specific competitive inhibitor of PP2A. In a mouse xenograft model of human pancreatic cancer, LB-100 produced significant radiosensitization with minimal weight loss. Furthermore, LB-100 decreased cell viability through caspase activation and G2/M cell-cycle arrest. LB100 enhanced daunorubicin cytotoxicity resulting in decreased xenograft volumes and improved overall survival.

KEYWORDS: LB-100 | supplier | PP2A inhibitor | LB-1 | LB100 | LB 100 | LB1 | LB 1 | CAS [1632032-53-1] | Non Selective (Tyrosine Specific Phosphomonoesters) | PP2A | Inhibitor | Enzymes